Healthpoint Biotherapeutics, Fort Worth, Texas, has initiated a phase III clinical trial investigating the efficacy of HP802-247 for the treatment of venous leg ulcers. HP802-247 is an investigational allogeneic living cell bioformulation containing keratinocytes and fibroblasts. The study is designed to evaluate complete wound closure in subjects receiving HP802-247 plus compression therapy compared with subjects receiving vehicle control plus compression therapy over the 12-week treatment period.

[black up pointing small triangle] Information: http://www.healthpointbio.com